Τίτλος:
Serum evaluation of angiogenic cytokines basic fibroblast growth factor,
hepatocyte growth factor and TNF-alpha in patients with myelodysplastic
syndromes: Correlation with bone marrow microvascular density
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Recent studies have documented that angiogenesis plays a significant
role in haematological malignancies, including mylodysplastic syndromes
(MDS). Basic fibroblast growth factor (b-FGF), Hepatocyte growth factor
(HGF) and Tumor necrosis factor-alpha (TNF-alpha) are multifunctional
cytokines that potently stimulate angiogenesis. The aim of the present
study was to evaluate the microvascular density (MVD) and the serum
levels of these angiogenic factors in patients with myelodysplastic
syndromes (MDS). In 61 patients with MDS, MVD was measured in bone
marrow biopsies and b-FGF, HGF and TNF-alpha were determined in the
serum of the same patients by enzyme-linked immunosorbent assay (ELISA).
Serum levels of b-FGF, HGF and TNF-alpha as well as MVD in the bone
marrow were increased in MDS patients compared to healthy controls (p <
0.0001). Levels of b-FGF, HGF and TNF-alpha were also significantly
higher in high-risk for leukemic transformation MDS than in low-risk (p
< 0.0001). Significant differences were also found regarding MVD in high
and low risk patients (p < 0.001). Both b-FGF and HGF levels were
significant predictors of survival (p < 0.0005, log-rank test). The
present study showed that serum levels of b-FGF, HGF and TNF-alpha are
significantly increased and dependent on the severity of MDS suggesting
that the determination of these parameters may offer considerable
information regarding disease progression and prognosis.
Συγγραφείς:
Alexandrakis, MG
Passam, FH
Pappa, CA
Damilakis, J and
Tsirakis, G
Kandidaki, E
Passam, AM
Stathopoulos, EN and
Kyriakou, DS
Περιοδικό:
International Journal of Immunopathology and Pharmacology
Εκδότης:
SAGE Publications Inc.
Λέξεις-κλειδιά:
angiogenesis; basic fibroblast growth factor; hepatocyte growth factor;
tumor necrosis factor-alpha; MDS; prognosis
DOI:
10.1177/039463200501800211
